629625-93-0

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-(2-methylpropyl)-, phenylmethyl ester
• CAS NO: 629625-93-0
• Molecular Formula: C16H24N2O2
• Molecular Weight: 276.379
• Mol File: 629625-93-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-(2-methylpropyl)-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-(2-methylpropyl)-, phenylmethyl ester(629625-93-0)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-(2-methylpropyl)-, phenylmethyl ester(629625-93-0)

Safety Data

• Hazardous Substances Data: 629625-93-0(Hazardous Substances Data)

Upstream product

• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 78-84-2 isobutyraldehyde 
• 78-77-3 Isobutyl bromide 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 5308-28-1 1-isobutylpiperazine 

Relevant articles and documents

Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in?vivo anti-tumor activity

Novel 1H-benzo[d]immidazole-4-carboxamide derivatives bearing five-membered or six-membered N-heterocyclic moieties at the 2-position were designed and synthesized as PARP-1 inhibitors. Structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values in the single or double digit nanomolar level. Some potent PARP-1 inhibitors also had similar inhibitory activities against PARP-2. Among all the synthesized compounds, compound 10a and 11e displayed strong potentiation effects on temozolomide (TMZ) in MX-1?cells (PF50?=?7.10, PF50?=?4.17). In?vivo tumor growth inhibition was investigated using compound 10a in combination with TMZ, and it was demonstrated that compound 10a could strongly potentiate the cytotoxicity of TMZ in MX-1 xenograft tumor model. Two co-crystal structures of compounds 11b and 15e complexed with PARP-1 were achieved and demonstrated a unique binding mode of these benzo-imidazole derivatives.

NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES

The present invention relates to a compound represented by the formula (I): (wherein, R3, R6, R7 and R21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.